Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | V. Vella et al., Cells, 2019, 8, 1017, doi:10.3390/cells8091017 | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | X. Wu et al., PNAS, Nov 2016, 113: E6965 - E6973 | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | I. V. Rassokhina et al., Steroids, 2016, 113: 29-37; doi.org/10.1016/j.steroids.2016.06.001 | |||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | A. M. Scherbakov et al., Exp. Cell Res., 2013, 319: 3150 – 3159, doi.org/10.1016/j.yexcr.2013.08.019 | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | I. H. Polat, Doctoral Thesis, 2016, University of Barcelona | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | A. M. Scherbakov et al., J. of Cellular Biochem., 2012, 113: 2147–2155 | |||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | A. M. Scherbakov et al., Chem. Biodiversity, 2019, 16: e1900332, DOI: 10.1002/cbdv.201900332 | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | A. Hermawan et al., Dissertation, 2015, Ludwig-Maximilians-Universität München | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | K. J. Lee et al., Exp. Cell Research, 2015, 336: 211-222; doi.org/10.1016/j.yexcr.2015.07.010 | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | Y. V. Kuznetsov et al., Europ. J. of Med. Chem., 2018, 143: 670-682, doi.org/10.1016/j.ejmech.2017.11.042 | |||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | A. M. Scherbakov et al., Frontiers in Pharmacology, 2018, 8:979, doi: 10.3389/fphar.2017.00979 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | D. Sorokin et al., Pharmaceuticals, 2020, 13(9): 206, doi.org/10.3390/ph13090206 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | A. M. Scherbakov et al., IUBMB, 2016, 68 (4): 281-292; DOI 10.1002/iub.1481 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | A. Hermawan, Ludwig-Maximilians-Universität München | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | Y. V. Kuznetsov et al., Steroids, 2018, doi.org/10.1016/j.steroids.2018.07.007 | |||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | K2 Transfection System | publication | B. Ljepoja et al., PLoS ONE, 2019, 14(11): e0224314, doi.org/10.1371/journal.pone.0224314 | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | miRNA | K2 Transfection System | publication | B. Ljepoja, Dissertation, 2019, Ludwig-Maximilians-Universität München | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | C. Thirukkumaran et al., PLOSONE 2017, DOI:10.1371/journal.pone.0168233 | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | oligonucleotide | DOTAP | publication | A. Avinó et al., Protocols in Nucleic Acid Chemistry, 2020, 77: e78, doi: 10.1002/cpnc.78 | |||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | Y. V. Kuznetsov et al., Eur. J. of Medicinal Chemistry, 2018, 143: 670e682, doi.org/10.1016/j.ejmech.2017.11.042 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | H.-K. Lee et al., BMC Cancer, 2015, 15:113; DOI: 10.1186/s12885-015-1118-z | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | stable transfection | K2 Transfection System | publication | B. Ljepoja et al., Scientific Reports, 2018, 8:6927, DOI:10.1038/s41598-018-25240-y | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | RNA-Interference | Metafectene PRO | publication | X. Wu et al., PNAS, Nov 2016, 113: E6965 - E6973 | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | U. K. Mukhopadhyay et al., Cytokine, 2016; 82: 70-79; doi.org/10.1016/j.cyto.2016.01.013 | |||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | M. Ansems et al., J Natl Cancer Inst, Jan 2010; 102: 54 - 68 | Link |